Briefly, compared to BRCA WT HRD-low BC, BRCA-mutated tumors were enriched in proliferation module gene sets (E2F target, G2M checkpoint, MYC targets, mitotic spindle signatures), but also in immune pathway (allograft_rejection signature), and mTORC1 pathway (Fig. 3A). This evidence concerns the gene MYC and breast cancer.